Fresh tariff deal to push pharma investment and innovation to US

EU PERSPECTIVES - Brussels hailed the EU-US trade agreement as a "stabilising force" in uncertain times. But the deal has rattled Europe's pharmaceutical sector, with a 15 per cent tariff on EU-made medicines now on the table. The uncertainty has already triggered a wave of research and development investment announcements in the United States. Reinforcing a trend: innovation is going west. Read more

Increasungly American / Photo: National Cancer Institute, USA (Unsplash)